Ocular Therapeutix OCUL Business Segments — D&A

Similar metrics at other companies

QURESingle Reportable — D&A

$2.96M-34.7%

SRRKSingle Reportable — D&A

$335K-14.8%

RGTISingle Reportable — D&A

$2.62M+43.0%

PAYOSingle Reportable — D&A

$18.92M+31.5%

MCRISingle Reportable — D&A

$10.47M-20.8%

AAPReportable — D&A

$58M+56.8%

Questions, answered.

What is Ocular Therapeutix's business segments — D&A?

Ocular Therapeutix (OCUL) reported business segments — D&A of $1.26M in Q1 2026.

How has Ocular Therapeutix's business segments — D&A changed year-over-year?

Ocular Therapeutix's business segments — D&A increased by 28.4% year-over-year, from $981K to $1.26M.

What is the long-term trend for Ocular Therapeutix's business segments — D&A?

Over 3 years (2022 to 2025), Ocular Therapeutix's business segments — D&A has grown at a 27.1% compound annual growth rate (CAGR), from -$2.11M to $4.33M.

What does business segments — D&A mean?

This metric represents the non-cash allocation of the cost of tangible and intangible assets over their useful lives within the company's primary business segment. It reflects the consumption of capital investments required to support the development and manufacturing of ophthalmic therapeutic products. Monitoring this helps investors understand the capital intensity of the company's operations.